Figure 1

Time course of thyroglobulin (Tg) in patients with controlled (stable disease or partial response; left) or progressive disease (right).
All patients display an initial decline in Tg after initiation of treatment with lenvatinib. Whereas the patients with long-term disease control present with transient fluctuations in Tg levels (left) over time, Tg rises (continuously) in the subjects with truly progressive disease (right).